Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomotaka Shimamura

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 13, 2006
[Capecitabine]Kensei Yamaguchi, Tomotaka Shimamura, Masahiro Tada
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 16, 2007
[Chemotherapy in advanced gastric cancer--to ensure timely and appropriate switch to subsequent treatment options]Kensei Yamaguchi, Tomotaka Shimamura, Tsutomu Ishikubo, et al.
Investigational New Drugs|May 26, 2011
Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancerTaroh Satoh, Kensei Yamaguchi, Narikazu Boku, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 25, 2006
Phase I-II study of biweekly paclitaxel administration with fixed-dose-rate cisplatin in advanced gastric cancerKensei Yamaguchi, Tomotaka Shimamura, Yoshito Komatsu, et al.
International Journal of Clinical Oncology|April 30, 2018
Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancerKohei Nakachi, Masaru Konishi, Masafumi Ikeda, et al.
Pancreas|April 24, 2018
SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1Yasunori Sato, Hideki Ueno, Tatsuya Ioka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2013
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST studyHideki Ueno, Tatsuya Ioka, Masafumi Ikeda, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 13, 2006
[Capecitabine]Kensei Yamaguchi, Tomotaka Shimamura, Masahiro Tada
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 16, 2007
[Chemotherapy in advanced gastric cancer--to ensure timely and appropriate switch to subsequent treatment options]Kensei Yamaguchi, Tomotaka Shimamura, Tsutomu Ishikubo, et al.
Investigational New Drugs|May 26, 2011
Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancerTaroh Satoh, Kensei Yamaguchi, Narikazu Boku, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 25, 2006
Phase I-II study of biweekly paclitaxel administration with fixed-dose-rate cisplatin in advanced gastric cancerKensei Yamaguchi, Tomotaka Shimamura, Yoshito Komatsu, et al.
International Journal of Clinical Oncology|April 30, 2018
Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancerKohei Nakachi, Masaru Konishi, Masafumi Ikeda, et al.
Pancreas|April 24, 2018
SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1Yasunori Sato, Hideki Ueno, Tatsuya Ioka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2013
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST studyHideki Ueno, Tatsuya Ioka, Masafumi Ikeda, et al.
Pageof 1